Author & year Diagnosis Intervention Number of participants (EPO/placebo) Age (yrs, EPO/placebo) Sex (males (females) in EPO/placebo) Outcome measure Outcomes measure time Bai and Gao 2018 Severe TBI 6000 IU, within 2 h, on days 3, 5, 10, and 15 120 (60/60) 41 (19)/44 (16) GOS scores & mortality & adverse events 10 wks Li et al. 2016 Severe TBI 100 units/kg, within 6 h, on days 3, 6, 9, and 12 146 (75/71) 49 (26)/41 (30) GOS scores & mortality & adverse events 3 mos Nichol et al. 2015 Moderate or severe TBI 40,000 IU, within 24 h, weekly for a max of 3 doses 602 (305/297) 30.5 (22.4-47.5)/30.5 (22.9-48.3) 256 (49)/246 (52) GOS-E score & mortality & adverse events 6 mos Aloizos et al. 2015 Severe TBI 10000 IU, within 6 h, 7 consecutive days 42 (24/18) 23 (19)/16 (2) GOS-E score & adverse events 6 mos Robertson et al. 2014 Severe TBI 500 IU/kg, 1st dose within 6 h, weekly for 2 more weeks 200 (102/98) 31.5 (23-48)/30.0 (22-44) 89 (12)/84 (14) GOS, DRS score & adverse events 6 mos Abrishamkar et al. 2012 Severe TBI with DAI 2000 U, on days 2, 4, 6, 8, and 10 54 (27/27) 27 (0)/27 (0) GOS & mortality 2 wks Nirula et al. 2010 Moderate or severe TBI 40,000 units within 6 h 16 (11/5) 8 (3)/3 (2) Serum NSE, S-100B, ICP values, mortality & adverse events 5 d
